Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Moderna secures COVID-19 vaccine delivery win before appeals court

12 April 2023 Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.

Americas

US govt wades into Moderna COVID row

15 February 2023 The pharma company is accused of using patented tech for a drug-delivery system without authorisation | Moderna sought to escape the suit by claiming that its contract with the US government conferred immunity.

Americas

Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit

30 August 2022 Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

More on this story

Editor's picks

Editor's picks

More features